Form 4: Butterfly Network CEO Brent Pfeiffenberger Receives Stock Options and Restricted Stock Units

Brent Pfeiffenberger, CEO of Butterfly Network, was granted stock options and restricted stock units (RSUs) on March 7, 2024, according to a recent SEC Form 4 filing.

Summary

• Butterfly Network's CEO, Brent Pfeiffenberger, received 104,550 stock options and 17,425 restricted stock units (RSUs) on March 7, 2024.
• The stock options have an exercise price of $5.32 and expire on March 7, 2034.
• The options vest 25% on March 7, 2025, and the remaining 75% vest in 36 equal monthly installments thereafter, contingent upon continued service.
• The RSUs vest 25% on March 7, 2025, with the remaining 75% vesting quarterly over the following three years, also subject to continued service.
• Each RSU represents the right to receive one share of Butterfly Network's common stock upon vesting.
• A power of attorney was executed on March 11, 2024, granting Douglas Carr and Gregory Russotti the authority to file Forms 3, 4, and 5 on Pfeiffenberger's behalf.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The granting of equity compensation is a standard practice and suggests confidence in the CEO's ability to drive future growth. However, it doesn't provide any concrete information about the company's current performance or future prospects.

Positives

• The grant of stock options and RSUs aligns the CEO's interests with those of the shareholders, incentivizing him to increase the company's value.
• The vesting schedule encourages long-term commitment from the CEO.

Future Outlook

The document does not contain specific forward-looking statements about the company's future performance, but the equity grants suggest an expectation of continued service and value creation by the CEO.

Industry Context

Granting stock options and RSUs to executives is a common practice in the technology and healthcare industries to incentivize performance and retain key personnel. The vesting schedules are designed to align executive compensation with long-term shareholder value.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the tech and biotech industries.
• Companies like Teladoc Health and Dexcom also utilize stock options and RSUs to incentivize their leadership teams.
• The vesting schedules described are typical, with vesting periods ranging from three to four years.

Stakeholder Impact

• Shareholders may view the equity grants positively as they align the CEO's interests with increasing shareholder value.
• Employees may see the grants as a sign of the company's commitment to its leadership.

Key Dates